Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Bioverativ Earns Approval for 4,000 IU Version for Hemophilia B Treatment Alprolix
March 20, 2018
- Toho to Thoroughly Implement Drug Distribution GL, Focus on Cost-Cutting in Response to Impact of Drug Pricing Reform: Pres.
March 20, 2018
- Takeda Bolstering Pitch for Inisync, Takecab in December: Anterio Ranking
March 19, 2018
- Ethical Drug Sales Up 3.6% in January on AbbVie Hep C Drug, Seasonal Factors
March 19, 2018
- EMA Accepts Filing for Xtandi’s CRPC Label Expansion
March 19, 2018
- Shionogi Nabs Rights to Osaka Upstart’s Tissue Regeneration-Inducing Peptide
March 16, 2018
- Japan Likely the Only Negative Growth Pharma Market in 2018-2022: IQVIA
March 16, 2018
- Rohto Wins Japan Exclusive Rights to JT’s JAK Inhibitor in Ophthalmology Field
March 16, 2018
- Ono Exercises Option to Ink New Autoimmune Disease Deal with Merus
March 15, 2018
- Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
March 15, 2018
- Kaketsuken, Meiji-Kumamoto JV, Ink Deal on Share Transfer of New Company, with Completion Date Set on July 2
March 15, 2018
- Re-Pricing Rule for Indication Expansions Mars I/O Development: MSD Japan Chief
March 14, 2018
- Gilead Japan Rolling Up Its Sleeves for Foray into Oncology/Inflammation Market
March 14, 2018
- Toyama Chemical Begins Patient Enrollment in Japan PIII Study of Avigan for SFTS
March 13, 2018
- EA Pharma’s Livact Now Available in Thailand
March 12, 2018
- Solifenacin Oral Suspension Approved in Europe for Pediatric NDO: Astellas
March 12, 2018
- Costa Saroukos Tapped as Takeda’s Global CFO
March 9, 2018
- Hiroo Ito Named New President of Actelion Pharmaceuticals Japan
March 9, 2018
- Daiichi Sankyo’s ADC DS-8201 Enters Global PII Study for Colorectal Cancer
March 9, 2018
- Aducanumab Trial Tweak Has No Impact on Probability of Success: Eisai CEO
March 9, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…